生物制剂治疗慢性鼻窦炎伴鼻息肉的真实世界流行病学结局:大数据分析
基于Clalit健康服务数据库的回顾性大数据分析,纳入2010至2024年间内镜鼻窦手术后接受度普利尤单抗或美泊利单抗治疗的861例CRSwNP患者(54.2%用度普利尤单抗,45.8%用美泊利单抗),62%合并哮喘。生物制剂显著减少抗生素和全身激素使用、社区诊所就诊、住院及再次手术率,血清嗜酸性粒细胞从520±440降至430±460 cells/μL。
要点
- 内镜鼻窦术后生物制剂治疗可减少CRSwNP患者抗生素和全身激素使用。
- 生物制剂降低社区诊所就诊、住院和再次内镜鼻窦手术率。
- 血清嗜酸性粒细胞从520±440降至430±460 cells/μL。
核心结论
- 内镜鼻窦术后生物制剂治疗与CRSwNP患者医疗资源利用和全身药物使用减少相关。
研究设计与样本
- 回顾性大数据分析,使用Clalit健康服务数据库,纳入2010至2024年内镜鼻窦手术后接受度普利尤单抗或美泊利单抗治疗的CRSwNP患者861例。
主要发现
- 861例患者中54.2%使用度普利尤单抗,45.8%使用美泊利单抗,62%合并哮喘,中位治疗时长25个月。
- 治疗前平均随访130±78个月,治疗后平均随访43±42个月。
- 生物制剂显著减少抗生素和全身激素使用、社区诊所就诊、住院及再次内镜鼻窦手术率。
- 血清嗜酸性粒细胞从520±440降至430±460 cells/μL。
临床怎么用
- 对于内镜鼻窦手术后仍疾病负担重的CRSwNP患者,可考虑生物制剂治疗以降低医疗资源利用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biologic therapy has emerged as a key treatment for chronic rhinosinusitis with nasal polyps (CRSwNP), particularly in refractory cases, but its effect on healthcare utilization is not well established. METHODOLOGY: We conducted a retrospective big-data analysis using the Clalit Health Services database, identifying all CRSwNP patients treated with dupilumab or mepolizumab following endoscopic sinus surgery (ESS) between 2010â€"2024. We assessed antibiotic and systemic steroid use, visits to clinics, emergency rooms (ER), hospitalizations, and repeat ESS before and after biologic initiation. RESULTS: Among 861 patients (54.2% on dupilumab, 45.8% on mepolizumab), 62% had asthma. Median therapy duration was 25 months. Mean follow-up was 130 ± 78 months before treatment and 43 ± 42 months after. Biologics significantly reduced antibiotic and systemic steroid use, as well as community clinic, hospitalization, and revision ESS rates. Serum eosinophils declined from 520 ± 440 to 430 ± 460 cells/μL. CONCLUSIONS: Post-ESS biologic therapy in CRSwNP patients is associated with reduced healthcare utilization and systemic medication use, highlighting its positive impact on disease burden and healthcare efficiency.
引用
- Zloczower E, Nyquist GG, Bebin A, et al. Real-world epidemiological outcomes of biologic therapy for chronic rhinosinusitis with nasal polyps: a big data analysis. Rhinology. 2026. PMID: 41486788. doi:10.4193/Rhin25.393
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。